{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:10Z","timestamp":1753891870146,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors. Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lutetium Oxodotreotide is an effective treatment for advanced neuroendocrine tumors, including those associated with ZES. However, the gastrointestinal toxicity induced by ZES can complicate the administration of PRRT. We present a case of a patient with metastatic G2 neuroendocrine tumor of the duodenum and ampulla of Vater who experienced severe gastrointestinal complications after the first PRRT cycle due to exacerbated ZES. The implementation of a prophylactic treatment with high-dose proton pump inhibitors before and after the subsequent PRRT cycles allowed for the successful completion of the therapy. This case highlights the importance of considering ZES-related complications in patients undergoing PRRT. Proactive management with high dose acid-suppressing therapy can significantly improve patient tolerance and treatment outcomes. Further research is needed to optimize the management of ZES patients undergoing PRRT.<\/jats:p>","DOI":"10.3389\/fonc.2025.1590478","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:10:20Z","timestamp":1747627820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications"],"prefix":"10.3389","volume":"15","author":[{"given":"Martina","family":"Di Franco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rexhep","family":"Durmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Liberata","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giacosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bann\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Filice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13267","article-title":"All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update","volume":"35","author":"Chatzipanagiotou","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00005792-200011000-00004","article-title":"Zollinger-Ellison syndrome. Clinical presentation in 261 patients","volume":"79","author":"Roy","year":"2000","journal-title":"Med (Baltimore)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2217\/ije-2017-0018","article-title":"Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing","volume":"4","author":"Metz","year":"2017","journal-title":"Int J Endocr Oncol"},{"key":"B4","article-title":"Gastrinoma","volume-title":"Endotext","author":"Jensen","year":"2000"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0642-8","article-title":"Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances","volume":"47","author":"Ito","year":"2012","journal-title":"J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2212dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B9","first-page":"46","article-title":"Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma","volume":"5","author":"Dumont","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25646","article-title":"Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of Malignant gastrinomas","volume":"117","author":"Grozinsky-Glasberg","year":"2011","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","article-title":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions","volume":"66","author":"Tapia Rico","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000461583","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1590478\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T04:10:22Z","timestamp":1747627822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1590478\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":12,"alternative-id":["10.3389\/fonc.2025.1590478"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1590478","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"article-number":"1590478"}}